Zoetis 重磅新聞 - 將推出醫冶狗隻心線蟲新藥

The largest animal-health company, received an upgrade on Monday ahead of the expected regulatory approval of Simparica Trio, an oral canine drug that is expected to generate big sales.
Goldman Sachs initiated coverage of the animal-health industry on Monday, rating Zoetis (ticker: ZTS) a Buy. It cited the expected introduction of Simparica Trio, which is under regulatory review in the U.S., Canada, Brazil, Australia and Japan, as a reason for the rating.

The drug, which is chewable, will be used to prevent heartworm disease, treat and control ticks and internal parasites. One of its advantages will be convenience, as it will allow pet owners to combine several drugs into one.

“Our upside case for Simparica Trio sees potential for $1.36 [billion] of revenue in 2022 and $1.14 of incremental EPS (net of cannibalization),” the Goldman note said.


https://www.barrons.com/articles/zoetis-stock-canine-drug-simparica-trio-animal-health-51568035966